IMS Anticipates Decline, And Opportunities, For Branded Generics
This article was originally published in PharmAsia News
Executive Summary
IMS Health anticipates government pricing pressure will make it harder for branded generics in emerging markets, but in the right market and with the right approach, large opportunities remain.
You may also be interested in...
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.